This indicates that quantifying ACE2 in the serum of NSCLC patients could be a valuable marker for identifying patients with high ACE2 expression on their tumor with a high specificity (91%) but limited sensitivity for low ACE2 expression (60%). The gene discussed is ACE2; the disease is neoplasm.